Sage Therapeutics (NASDAQ:SAGE) Reaches New 12-Month Low at $15.06

Sage Therapeutics, Inc. (NASDAQ:SAGE) reached a new 52-week low during trading on Tuesday . The company traded as low as $15.06 and last traded at $15.27, with a volume of 913976 shares changing hands. The stock had previously closed at $15.32.

Analyst Ratings Changes

SAGE has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, March 26th. Bank of America lowered shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $24.00 to $14.00 in a research note on Wednesday. Morgan Stanley boosted their price target on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. Wedbush reiterated a “neutral” rating and set a $24.00 price target on shares of Sage Therapeutics in a research note on Wednesday. Finally, TD Cowen cut their price target on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and a consensus price target of $39.89.

Sage Therapeutics Price Performance

The firm has a market cap of $755.58 million, a PE ratio of -1.39 and a beta of 0.86. The business has a 50-day moving average price of $20.06 and a two-hundred day moving average price of $20.96.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. The firm had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm’s quarterly revenue was up 2621.5% compared to the same quarter last year. During the same quarter last year, the business posted ($2.47) EPS. Equities analysts expect that Sage Therapeutics, Inc. will post -6.06 earnings per share for the current fiscal year.

Institutional Trading of Sage Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SAGE. RTW Investments LP acquired a new stake in Sage Therapeutics in the 3rd quarter worth about $105,976,000. Goldman Sachs Group Inc. grew its holdings in shares of Sage Therapeutics by 252.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,106,276 shares of the biopharmaceutical company’s stock worth $35,733,000 after purchasing an additional 792,819 shares during the period. State Street Corp grew its holdings in shares of Sage Therapeutics by 30.8% during the 1st quarter. State Street Corp now owns 2,835,356 shares of the biopharmaceutical company’s stock worth $93,850,000 after purchasing an additional 666,826 shares during the period. BlackRock Inc. grew its holdings in shares of Sage Therapeutics by 13.7% during the 3rd quarter. BlackRock Inc. now owns 4,822,063 shares of the biopharmaceutical company’s stock worth $188,833,000 after purchasing an additional 580,250 shares during the period. Finally, Morgan Stanley grew its holdings in shares of Sage Therapeutics by 145.5% during the 3rd quarter. Morgan Stanley now owns 863,932 shares of the biopharmaceutical company’s stock worth $17,780,000 after purchasing an additional 512,021 shares during the period. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.